STOCK TITAN

PetVivo Holdings Inc - PETV STOCK NEWS

Welcome to our dedicated news page for PetVivo Holdings (Ticker: PETV), a resource for investors and traders seeking the latest updates and insights on PetVivo Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PetVivo Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PetVivo Holdings's position in the market.

Rhea-AI Summary
PetVivo Holdings, Inc. (PETV) to dual list shares on Upstream for global trading starting March 5, 2024. Shareholders to receive commemorative NFT. Upstream offers real-time trading, transparent orderbook, and digital collectibles for participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PetVivo Holdings, Inc. will showcase its innovative veterinary medical device, SPRYNG™ with OsteoCushion™ Technology, at the Western Veterinary Conference. The conference, hosting over 15,000 participants, offers a platform for PetVivo to engage with industry professionals and promote its joint pain management solution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
none
-
Rhea-AI Summary
PetVivo Holdings, Inc. (Nasdaq: PETV) announces financial results for the third quarter of 2024, highlighting a multi-distribution sales strategy and the addition of a new Board member. The company raised $1.2 million in a private offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
earnings
Rhea-AI Summary
PetVivo Holdings, Inc. announced the release of the results of a clinical study conducted by Inotiv, Inc., which examined the safety of intra-articular injections of collagen-elastin hydrogel microparticulates (Spryng™ with OsteoCushion™ Technology) into the joints of cats. The study demonstrated the excellent safety profile of Spryng when injected into 40 joints across 10 individual cats, showing similar results to a benign control in terms of incidences of lameness, joint swelling, or pain after injection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
clinical trial
-
Rhea-AI Summary
PetVivo Holdings, Inc. will report financial results on February 12, 2024, after market close. The company is focused on commercializing innovative medical therapeutics for animals. A conference call to discuss the results will be held at 4:00 p.m. CT (5:00 p.m. ET) on the same day. The webcast and earnings release materials can be accessed on PetVivo’s Investor Relations website. PetVivo uses its Investor Relations website to disclose material nonpublic information and comply with its disclosure obligations under Regulation FD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
earnings
-
Rhea-AI Summary
PetVivo Holdings, Inc. announces the results of a clinical study examining the safety of intra-articular injections of a collagen-elastin hydrogel microparticulate biomaterial into the joints of dogs. The study demonstrated the safety profile of the veterinary medical device, Spryng with OsteoCushion Technology, in managing joint-related afflictions in companion animals. The data provided from the study indicates that the use of Spryng was similar to a benign control in regard to incidences of lameness, joint swelling, or pain after injection, with post-injection outcomes often no different than pre-injection baseline measures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
clinical trial
Rhea-AI Summary
PetVivo Holdings, Inc. announces the issuance of a notice of allowance for a patent application by the United States Patent and Trademark Office (USPTO) related to the Company’s proprietary biomaterials and corresponding products. The patent provides protection for a broad range of proprietary products, including the biocompatible sponge-like particles used in PetVivo’s signature product, Spryng™ with OsteoCushion™ Technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
-
Rhea-AI Summary
PetVivo Holdings, a company specializing in innovative medical devices and therapeutics for companion animals, will be participating in The Microcap Conference from January 30 to February 1, 2024. CEO John Lai will be presenting on January 31 & February 1, 2024, with the management team conducting one-on-one meetings throughout the conference. Interested parties can register to attend on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
none
-
Rhea-AI Summary
PetVivo Holdings, an emerging biomedical device company (NASDAQ: PETV & PETVW), will exhibit its lead product, Spryng with OsteoCushion Technology, at the Veterinary Meeting & Expo Conference from January 14th to 17th, 2024. The intra-articular injectable veterinary medical device is designed to manage joint-related afflictions such as osteoarthritis, and the company aims to network with industry leaders at the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
none
Rhea-AI Summary
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has entered into a definitive distribution agreement with Covetrus North America, LLC to market and promote its veterinary medical device, Spryng™ with OsteoCushion™ technology, throughout the United States. Covetrus sales and marketing activities will commence on January 1, 2024. This strategic partnership aims to benefit the veterinary industry, the veterinarians, the animals receiving Spryng, and the owners benefiting from the enhanced medical outcomes of their animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
none
PetVivo Holdings Inc

Nasdaq:PETV

PETV Rankings

PETV Stock Data

19.79M
11.85M
35.9%
4.86%
0.82%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Minneapolis

About PETV

petvivo, inc is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. petvivo believes that it can leverage the investments in the human biomaterials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. petvivo's strategy is to in-license proprietary products from human medical device companies specifically for use in pets. petvivo, inc, gel-del technologies, inc. and cosmetalife a corporation are all wholly-owned subsidiaries of petvivo holdings, inc.